Cresco Labs (OTCMKTS:CRLBF) had its price objective lifted by Cantor Fitzgerald from $16.00 to $18.00 in a research note issued to investors on Thursday, Analyst Ratings Network reports. They currently have an overweight rating on the stock.
CRLBF has been the subject of several other reports. Stifel Nicolaus assumed coverage on shares of Cresco Labs in a research report on Wednesday, July 22nd. They set a buy rating and a $10.00 target price for the company. Roth Capital lifted their target price on shares of Cresco Labs from $8.00 to $11.00 and gave the stock a buy rating in a research note on Friday, August 21st. Finally, Piper Sandler lifted their target price on shares of Cresco Labs from $8.00 to $12.00 and gave the stock an overweight rating in a research note on Friday, August 21st. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $11.45.
Shares of Cresco Labs stock opened at $8.77 on Thursday. Cresco Labs has a 1 year low of $1.94 and a 1 year high of $9.50. The company has a 50 day simple moving average of $7.45 and a two-hundred day simple moving average of $5.78.
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells medical cannabis and medical cannabis products in the United States. It offers cannabis in flowers, live concentrates, and liquid live resins under the Cresco and Reserve brands; soft gels, tinctures, and lotions under the Remedi brand; gummies, fruit chews, hard sweets, and chocolates under the Mindy's brand; and vape pens, popcorn, shake, pre-rolls, and shorties under High supply brand.
Recommended Story: Example of operating income, EBIT and EBITDA
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.